FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy By Ogkologos - July 1, 2026 53 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CADENZA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR 31-Year-Old Mother Dies of Cancer After Her Chemotherapy Was Paused During... October 19, 2020 A Painful Breast Lump May Be Mistaken For Cancer When It’s... July 15, 2020 FDA Grants Regular Approval to Dostarlimab-gxly for dMMR Endometrial Cancer February 20, 2023 EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib March 27, 2026 Load more HOT NEWS New option to treat advanced oesophageal cancer approved for NHS in... 4-Year-Old Boy Calls Police To Tell Them About His Toys, Cop... Attorney Donates $30K In Gift Cards So Parents Can Purchase Gifts... Time to take on 9 new Cancer Grand Challenges
